GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » 5-Year ROIIC %

Biocept (Biocept) 5-Year ROIIC % : -91.17% (As of Dec. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Biocept 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. Biocept's 5-Year ROIIC % for the quarter that ended in Dec. 2022 was -91.17%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Biocept's 5-Year ROIIC % or its related term are showing as below:

BIOCQ's 5-Year ROIIC % is ranked worse than
87.79% of 213 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.09 vs BIOCQ: -91.17

Biocept 5-Year ROIIC % Historical Data

The historical data trend for Biocept's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept 5-Year ROIIC % Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 222.60 -187.69 5.00 88.55 -91.17

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -91.17 - -

Competitive Comparison of Biocept's 5-Year ROIIC %

For the Diagnostics & Research subindustry, Biocept's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocept's 5-Year ROIIC % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biocept's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Biocept's 5-Year ROIIC % falls into.



Biocept 5-Year ROIIC % Calculation

Biocept's 5-Year ROIIC % for the quarter that ended in Dec. 2022 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -31.8582663 (Dec. 2022) - -21.18347 (Dec. 2017) )/( 17.063 (Dec. 2022) - 5.354 (Dec. 2017) )
=-10.6747963/11.709
=-91.17%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Biocept  (OTCPK:BIOCQ) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Biocept 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Biocept's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121